LYEL NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Lyell Immunopharma Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 12.94 USD
2.5% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -32.4% below the Trend Line and sits at 10.2% of its 52-week range. The latest completed week returned 2.5%, after a -7.9% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is neither clearly cheap nor expensive. Options positioning is bearish with 38/100 conviction, while the latest news-sentiment score is 51/100. Near-term considerations: earnings are due in 9d.

Setup score 22 out of 100
Latest Close 12.94 USD 31 Jul 2026
1W Return 2.5% latest completed week
4W Return -7.9% short-term follow-through
12W Return -33.1% quarterly tape
Trend Breadth 50.0% 26 of 52 weeks active
Volume Ratio 1.0x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 2.5% Latest completed week; four-week move -7.9%. Indicator stack 28/27 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Bearish 38/100 conviction; expected move 11.8%. News sentiment 51/100 58 relevant articles in the latest sentiment read. Event risk 9d Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -32.4% below the Trend Line and sits at 10.2% of its 52-week range. The latest completed week returned 2.5%, after a -7.9% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.0x the 13-week average. Participation is around or above normal and provides reasonable confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0112-week average 0.12

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.01Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -7.9% over four weeks, -33.1% over 12 weeks, and 17.4% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W2.5%
4W-7.9%
12W-33.1%
26W-46.1%
52W17.4%
Active trend streak0 weeks
Active weeks in one year26
Trend breadth50.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-1.15Latest activity-pressure read.
Pressure change-23.5%Four-week change in activity pressure.
Leadership-38.08Latest relative-leadership reading.
RS change-8.6%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 82% Model confidence 78%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength8/100Blend of value, momentum, and quality. Underlying universe rank 93; rank 1 is best.
Value31/100Relative valuation strength. Underlying universe rank 70; rank 1 is best.
Quality2/100Profitability and accounting quality. Underlying universe rank 99; rank 1 is best.
Momentum26/100Medium-term price momentum. Underlying universe rank 75; rank 1 is best.
Growth12/100Revenue and earnings growth. Underlying universe rank 89; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
9506.8x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-52.7%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-7422.6%
Gross profit retained from each unit of revenue.
Operating margin
-804577.4%
Operating profit retained from revenue.
Free-cash-flow margin
-429590.3%
Free cash flow generated from revenue.
Return on invested capital
-80.7%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-52.3%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
1/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-17.0%
Net share repurchases relative to market value.
Shareholder yield
-17.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.2x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBearish

LYEL shows bearish options pressure with a 38/100 conviction score, put-call volume ratio of 1.14, expected move of 11.8%, and Sharemaestro trend signal inactive.

Conviction38/100
Expected move11.8%
Put/call volume1.14
Pressure-19
Speculation8
Volatility74
Trend agreement79
Open options detail
Insider activity7 / 9

7 acquisitions and 9 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment51/100

Weighted news tone is neutral across 58 relevant articles.

14 positive · 36 neutral · 8 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings9dNext report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
Options expected move11.8%Nearest-chain priced movement where available.
52-week drawdown-71.2%Distance below the 52-week high.
13-week volatility12.0%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher10 of 2616 weeks finished lower.
Best week+21.0%Week of 3 Jul.
Worst week-30.9%Week of 5 Jun.
Latest week+2.5%Week of 31 Jul.

Shape of recent returns

Strong gains8
Modest gains2
Flat weeks0
Modest losses2
Sharp losses14
Recent vol12.0%13-week weekly-return volatility.
Base vol12.1%52-week weekly-return volatility.
Up/down split24/28Count of positive and negative weeks in the 52-week window.
Average skew10.7% / -7.3%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape25/100

Trend, activity pressure, participation, and risk combine to a 25/100 tape read.

 Indicator analysis9/100

Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.

Activity pressure 0.01; No reversal markers Factors15/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 90; Small Cap Core rank 78 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options54/100

LYEL shows bearish options pressure with a 38/100 conviction score, put-call volume ratio of 1.14, expected move of 11.8%, and Sharemaestro trend signal inactive.

Bearish · Put-side pressure · Expected move 11.8% Sentiment51/100

Weighted news tone is neutral across 58 relevant articles.

LYEL|Lyell Immunopharma Inc|Price:13.710|Chg%:+0.740 Insiders7 / 9

7 acquisitions and 9 disposals in the latest 180-day insider tape.

 Earnings9d

Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202612.94 USD2.5%19.16 USD25.09 USD-1.15-38.08791.1KOff
24 Jul 202612.63 USD-5.2%19.69 USD25.34 USD-1.06-39.28622.3KOff
17 Jul 202613.32 USD-11.3%20.44 USD25.64 USD-0.93-37.12758.1KOff
10 Jul 202615.01 USD6.8%21.11 USD25.96 USD-0.86-31.981.0MOff
3 Jul 202614.05 USD21.0%21.75 USD26.24 USD-0.93-35.05943.4KOff
26 Jun 202611.61 USD-8.9%22.13 USD26.53 USD-1.02-45.792.3MOff
19 Jun 202612.74 USD-5.6%22.54 USD26.86 USD-1.07-43.19808.5KOff
12 Jun 202613.50 USD12.8%22.75 USD27.20 USD-1.12-38.17612.8KOff
5 Jun 202611.97 USD-30.9%22.87 USD27.52 USD-1.16-43.90837.7KOff
29 May 202617.33 USD-0.7%23.05 USD27.80 USD-1.16-22.79340.9KOff
22 May 202617.46 USD-2.6%23.03 USD28.14 USD-1.10-19.63421.5KOff
15 May 202617.92 USD-7.3%23.04 USD28.40 USD-0.92-16.09334.6KOff
8 May 202619.33 USD-7.2%22.99 USD28.64 USD-0.63-9.24252.9KOff
1 May 202620.83 USD-7.1%22.90 USD28.84 USD-0.573.89290.9KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.